EPS for Portola Pharmaceuticals (PTLA) Expected At $-1.50; 7 Analysts Covering Pearson plc (LON:PSON)

October 13, 2017 - By Darrin Black

Among 25 analysts covering Pearson PLC (LON:PSON), 7 have Buy rating, 6 Sell and 12 Hold. Therefore 28% are positive. Pearson PLC had 311 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Tuesday, May 3 by Goldman Sachs. The stock of Pearson plc (LON:PSON) has “Buy” rating given on Wednesday, November 11 by AlphaValue. As per Thursday, February 2, the company rating was maintained by Liberum Capital. Liberum Capital maintained it with “Sell” rating and GBX 470 target in Friday, November 4 report. The firm has “Sell” rating given on Wednesday, June 15 by Liberum Capital. AlphaValue maintained Pearson plc (LON:PSON) on Thursday, December 24 with “Buy” rating. The stock has “Neutral” rating by Macquarie Research on Monday, February 27. BNP Paribas maintained the shares of PSON in report on Monday, November 9 with “Neutral” rating. Goldman Sachs maintained the shares of PSON in report on Monday, August 8 with “Sell” rating. Goldman Sachs maintained it with “Sell” rating and GBX 495 target in Monday, June 19 report. See Pearson plc (LON:PSON) latest ratings:

11/10/2017 Broker: Shore Capital Rating: Hold Maintain
02/10/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 330.00 New Target: GBX 330.00 Maintain
28/09/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 330.00 New Target: GBX 330.00 Maintain
27/09/2017 Broker: BNP Paribas Rating: Outperform New Target: GBX 700.00 Upgrade
27/09/2017 Broker: Deutsche Bank Rating: Sell Old Target: GBX 600.00 New Target: GBX 470.00 Downgrade
18/09/2017 Broker: Goldman Sachs Rating: Sell New Target: GBX 495.00 Maintain
18/09/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 330.00 New Target: GBX 330.00 Maintain
14/09/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 330.00 New Target: GBX 330.00 Maintain
14/09/2017 Broker: Credit Suisse Rating: Neutral Old Target: GBX 690.00 New Target: GBX 690.00 Maintain
08/09/2017 Broker: Liberum Capital Rating: Sell Old Target: GBX 330.00 New Target: GBX 330.00 Maintain

Analysts expect Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report $-1.50 EPS on November, 6.They anticipate $0.14 EPS change or 8.54% from last quarter’s $-1.64 EPS. After having $-1.22 EPS previously, Portola Pharmaceuticals Inc’s analysts see 22.95% EPS growth. About 501,320 shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since October 13, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Pearson plc is a learning company. The company has market cap of 5.26 billion GBP. The Firm delivers learning through providing a range of educational services and products to institutions, governments, professional bodies and individual learners. It currently has negative earnings. The Firm operates through three divisions, which include North America, Core and Growth.

The stock increased 2.72% or GBX 16.89 on October 13, reaching GBX 638.89. About 4.08M shares traded or 76.62% up from the average. Pearson plc (LON:PSON) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.32 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Since May 31, 2017, it had 1 buy, and 1 sale for $54.68 million activity. Another trade for 119,442 shares valued at $3.80M was bought by BIRD JEFFREY W. Shares for $58.48M were sold by Maxwell (Mauritius) Pte Ltd.

Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It dropped, as 17 investors sold Portola Pharmaceuticals Inc shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Nicholas Invest Prtnrs L P has 0.36% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 91,175 shares. Moreover, Bankshares Of Ny Mellon has 0% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Rhenman And Ptnrs Asset Ab has invested 0.89% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Edge Wealth Ltd stated it has 75 shares or 0% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,078 shares. Utd Service Automobile Association reported 0.02% stake. Eam Investors Llc holds 0.6% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 64,361 shares. Alliancebernstein Ltd Partnership holds 105,150 shares. Millennium Ltd Co holds 0.03% or 250,941 shares. Brown Brothers Harriman And holds 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA) or 284 shares. Bogle Mngmt L P De, Massachusetts-based fund reported 31,851 shares. Balyasny Asset Mngmt Lc has invested 0.08% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Airain Ltd reported 0.03% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Employees Retirement Association Of Colorado has invested 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). 198,903 were reported by Tourbillon Prtnrs Lp.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com